Le Lézard
Classified in: Health
Subject: FDA

NEOS Cranial LOOPtm Receives FDA Clearance for CustomizedBonetm Use


CANTON, Conn., April 2, 2024 /PRNewswire/ -- Kelyniam Global (OTC:KLYG) and Fin-ceramica, Faenza S.p.a., makers of custom cranial implants, announced today that the NEOS Surgery Cranial LOOPtm fixation system has received 510(k) clearance from the FDA for use with Finceramica's CustomizedBonetm hydroxyapatite cranial implant.

The Cranial LOOPtm family of cranial fixation devices is a smart system made of PEEK-OPTIMAtm, a biocompatible polymer, for securely fixing bone flaps after craniotomies. With more than 10 years of market experience, Cranial LOOPtm is being used in public and private hospitals in 25 countries worldwide. Cranial LOOPtm was first cleared by the FDA in 2010.  The most recent 510k clearance is for use specifically with Finceramica's CustomizedBonetm hydroxyapatite cranial implant. 

Ross Bjella, Kelyniam's CEO, said, "This approval will further boost Kelyniam's sales momentum which started in Q4 last year. Alongside the low infection rate and pediatric indication, the rapid fixation provided by the Cranial LOOPtm system is now an added benefit for neurosurgeons choosing CustomizedBonetm for their patients."

Since 2004 over 9000 CustomizedBonetm hydroxyapatite implants have been sutured in place. Hydroxyapatite, similar to human bone, facilitates seamless osteo-integration into patients' skulls. CustomizedBonetm is internationally recognized for its reduced infection risk and is indicated for use in children as young as 7 years old. 

The NEOS Surgery Cranial LOOPtm system offers rapid implant fixation in under two minutes using just three devices. Crafted from PEEK (poly ether ether ketone), it ensures radiolucency for artifact-free imaging (CT and MRI) during post-operative monitoring. Cost-wise, Cranial LOOPtm is comparable to traditional plate and screw systems. Kelyniam exclusively distributes CustomizedBonetm implants with the NEOS Cranial LOOPtm in the U.S.

About Finceramica
Fin-Ceramica Faenza S.p.A. founded in as a spin-off from the Institute for Science and Technology for Ceramics (ISTEC-CNR) in Faenza, Italy, epitomizes Italian excellence. Acquired by the Tampieri Financial Group, Finceramica seamlessly blends ceramic tradition with biomedical innovation.  Specializing in organic materials, the company creates medical solutions for bone and cartilage repair. These biomaterials promote rapid recovery by facilitating human cell colonization. Notably, CustomizedBonetm implants enable simultaneous cancer extirpation and cranial cavity reconstruction. Finceramica's global expertise focuses on excellence in niche products that significantly improve patients' lives.

About Kelyniam

Kelyniam Inc. specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers.  The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes. Kelyniam's web site address is www.Kelyniam.com.

As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; changes in the status of ability to market products; and the risks described from time to time in the Company's SEC reports. 

SOURCE Kelyniam Global Inc


These press releases may also interest you

at 18:15
Andlauer Healthcare Group Inc. ("AHG" or the "Company") today reported its financial results for the three-month period ended March 31, 2024 ("Q1 2024"). Q1 2024 Summary Revenue totaled $161.1 million, a decrease of 2.2% from $164.8 million for the...

at 18:02
The story of AHRC Nassau is one of love and relentless advocacy by parent advocates seeking to create a better world for their children with intellectual and developmental disabilities (I/DD). From a small support group of a dozen parents came a...

at 18:00
Nektar Therapeutics will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review...

at 17:41
TIME has included the co-chairs of the National Kidney Foundation (NKF)/ American Society of Nephrology (ASN) Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases, among its first-ever list of the 100 most influential people...

at 17:33
Cheung Aesthetics & Wellness, a leading Chicago dermatology practice, is among the first to offer groundbreaking technology that reverses facial aging and reduces wrinkles without discomfort, needles, or downtime. The clinic is hosting "Spring...

at 17:31
The surge in demand for angioplasty balloons and stents is mainly driven by the increasing prevalence of cardiovascular diseases (CVDs), the growing preference for minimally invasive procedures, and advancements in drug-coated/drug-eluting balloon...



News published on and distributed by: